Piper Sandler Initiates Coverage On Allogene Therapeutics with Overweight Rating, Announces Price Target of $11
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler has initiated coverage on Allogene Therapeutics (NASDAQ:ALLO) with an Overweight rating and a price target of $11.
May 31, 2024 | 9:53 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler has initiated coverage on Allogene Therapeutics with an Overweight rating and a price target of $11, indicating a positive outlook for the stock.
The initiation of coverage with an Overweight rating and a price target of $11 by Piper Sandler suggests a positive outlook for Allogene Therapeutics. This could lead to increased investor interest and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100